Preoperative brain natriuretic peptide (BNP) is a better predictor of adverse cardiac events compared to preoperative scoring system in patients who underwent abdominal surgery

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a clinical trial.

A variety of clinical scoring systems have been developed to predict adverse cardiovascular events.

The researchers present a prospective, single-center, observational cohort study of patients undergoing major abdominal surgery and evaluate the role of BNP in predicting adverse cardiac events.

Who Took Part

According to the abstract, 205 patients were involved.

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

A total of 205 patients were included in the study.

All patients were assessed by a cardiological clinical evaluation, a 12-lead ECG report, and a preoperative and postoperative blood sample for plasmatic BNP assessment.

How the Study Was Run

The primary end point was the predictive power of preoperative BNP levels for adverse cardiac events until 30 days after discharge.

What Was Measured

The researchers present a prospective, single-center, observational cohort study of patients undergoing major abdominal surgery and evaluate the role of BNP in predicting adverse cardiac events.

The subject headings attached to it are Abdomen, Biomarkers, Cardiovascular Diseases, Decision Support Techniques, Logistic Models, Natriuretic Peptide, Brain and Postoperative Complications.

What This Means in Plain Language

This is a clinical trial of BNP (Nesiritide) in 205 patients.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (World journal of surgery), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.